Selexis SA to Partner at the BIO 2006 Annual International Convention
Selexis to Participate in the Business Forum’s One-on-one Partnering Meetings
Geneva, Switzerland – March 17, 2006 - Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic proteins announced today that representatives from the Company will be participating in the BIO 2006 Business Forum’s Partnering Meetings being held April 10 - 12, 2006 in Chicago, Illinois, at the McCormick Convention Center. Selexis CEO, Dr. Igor Fisch and Dr. Cori Gorman, Head of Business Development will be taking part in the pre-scheduled meetings.
Companies or individuals attending BIO 2006 can schedule meetings with Selexis (registration required) by visiting: http://business-forum.bio.org/opencms/bf/2006/partnering/index.jsp
Selexis Partnering Schedule
- Monday, April 10 Business Forum - 8:00 AM - 5:30 PM
McCormick Place, South Building, Hall A2
- Tuesday, April 11 Business Forum - 8:00 AM - 5:30 PM
McCormick Place, South Building, Hall A2
- Wednesday, April 12 Business Forum - 8:00 AM - 5:30 PM
McCormick Place, South Building, Hall A2
For companies or individuals not participating in partnering meetings, Selexis will be co-exhibiting with BioAlps at the Switzerland Pavilion in booth number 1133. For the exhibit hall schedule, visit: http://www.bio.org/events/2006/exhibitors/sched.asp
About Selexis
Selexis is a privately held biotechnology company dedicated to the development of expert
services and technologies for comprehensive and rapid solutions for stable, high yield cell line
development and protein manufacturing for therapeutic drugs. The Company’s unique seven
step, high through put process, which includes the forth generation patented MARtech™,
reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection
to isolating cell clones) without any change in the scale-up process. For more information please
visit www.selexis.com